ABSTRACT
Ovarian cancer is the leading cause of death in women suffering from cancer, with a high mortality rate in gynecological cancer. Poly(ADP-ribose)polymerase(PARP)inhibitors cause targeted tumor cell death in homologous recombination(HR)-deficient cancers, including breast cancer susceptibility gene(BRCA)tumors, and the mechanism is called “synthetic lethality”. At present, there are three PARP inhibitors approved by FDA for the treatment of advanced ovarian cancer with BRCA-mutation. This paper reviews the role of PARP inhibitors in the treatment of ovarian cancer in clinical trial, elaborates the therapeutic mechanism of PARP inhibitors, and lights the way for the development of anti-ovarian cancer drugs.
ABSTRACT
Ovarian cancer is the leading cause of death in women suffering from cancer,with a high mortality rate in gyneco?logical cancer. Poly(ADP-ribose)polymerase(PARP)inhibitors cause targeted tumor cell death in homologous recombination(HR)-deficient cancers,including breast cancer susceptibility gene(BRCA)tumors,and the mechanism is calledsynthetic lethality. At present,there are three PARP inhibitors approved by FDA for the treatment of advanced ovarian cancer with BRCA-mutation. This pa?per reviews the role of PARP inhibitors in the treatment of ovarian cancer in clinical trial,elaborates the therapeutic mechanism of PARP inhibitors,and lights the way for the development of anti-ovarian cancer drugs.
ABSTRACT
MircoRNAs (miRNAs) are widely existing inorganisms, non-coding small RNA. MircoR-NAs play important role in cell proliferation, apoptosis, stress resistance and fat metabolism. In vitro studies indicate that miRNAs are important factors in platinum resistance of ovarian cancer cell lines. However, the pathway of platinum resistance of ovarian cancers is complex. Studies find miRNA expression play important roles in the sensitivity of platinum resistance of ovarian cancer cell lines , and can be used as an early alert for platinum resistance. Changing the expression of miRNA even can reverse the platinum resistance . But the regular role of miRNAs in target genes network is still unconfirmed. Thus, more studies about miRNA in vivo and animal tumor models are needed to identify the function of miRNAs in platinum resistance of ovarian cancer.
ABSTRACT
Objective To evaluate the effect of Ganoderma lucidum on drug resistance of the cisplantin-resistant ovarian cancer cell line(A2780CP).Methods The A2780CP cells were randomly divided into control group and test group.The cells in control group and test group were incubated in culture media alone and in culture media containing Ganoderma lucidum 0.5 mg/ml for 48 h respectively.The resistance index(RI) of A2780CP was determined by WST-1 assay.The expression of Akt,Bcl-2 and p53 protein was measured by Western blot.Results The RI was significantly deeressed,the expression of Akt and Bcl-2 protein was down-regulated,while p53 protein expression was up-regulated in test group as compared with control group(P<0.05).Conclusion Ganoderma lueidum can reduce the resistance of A2780 CP cells to cisplantin by down-regulating the expression of Akt and Bcl-2 and up-regulating p53 expression in A2780CP cells.